Drug Database · Clinicians

Granisetron

Brands (8) Granon, Frezitron, Grakytil…Show all

US brand (reference label): SUSTOL; not a Philippine-registered brand.

Serotonin-3 Receptor Antagonist (Serotonin 3 Receptor Antagonists) US FDA class
Antiemetic and antinauseant (serotonin (5HT3) antagonist); Serotonin (5HT3) antagonist; and others PH FDA category

Rx · Prescription drug9 PH productsVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f7c7ffdd-8270-4030-bc1e-a1cb28a6de56, version date April 30, 2026 (SUSTOL · Heron Therapeutics, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. SUSTOL is a serotonin-3 (5-HT 3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

(1)

Contraindications

4 CONTRAINDICATIONS SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or to any of the other 5-HT 3 receptor antagonists [see Warnings and Precautions (5.3), Description (11)]. Hypersensitivity to granisetron, any of the components of SUSTOL, or to any of the other 5-HT 3 receptor antagonists. (4, 5.3)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Administration (2.1): For subcutaneous injection only. Intended for administration by a healthcare provider. Administer in skin of the back of the upper arm or in the skin of the abdomen at least 1 inch away from the umbilicus. Do not administer anywhere the skin is burned, hardened, inflamed, swollen, or otherwise compromised.

Due to the viscosity, administration requires a slow, sustained injection over 20 to 30 seconds. Recommended Dosage (2.2): The recommended dosage in adults is 10 mg administered as a single subcutaneous injection at least 30 minutes before the start of emetogenic chemotherapy on Day 1. Do not administer SUSTOL more frequently than once every 7 days.

See full prescribing information for recommended dosage of concomitant dexamethasone. Renal Impairment (2.3): In patients with moderate renal impairment (Clcr 30-59 mL/min), administer SUSTOL not more frequently than once every 14 days. Avoid SUSTOL in patients with severe renal impairment (CLcr < 30 mL/min).

2.1 Important Administration Instructions

2.1 Important Administration Instructions For subcutaneous injection only. SUSTOL is intended for administration by a health care provider. SUSTOL is supplied as a refrigerated kit consisting of a single-dose, pre-filled, sterile syringe, a special thin walled 18 Ga 5/8" administration needle, two syringe warming pouches, and a Point Lok ® needle protection device.

See the SUSTOL Instructions for Use included in the kit for complete administration instructions with illustrations. Do not substitute non-kit components for any of the components from the kit for administration. Preparation At least 60 minutes prior to administration, remove the SUSTOL kit from refrigeration. Unpack the kit to allow the SUSTOL syringe and all other contents to warm to room temperature.

Activate one of the syringe warming pouches, and wrap the SUSTOL syringe in the warming pouch for 5 to 6 minutes to warm SUSTOL to body temperature. Prior to administration, inspect the SUSTOL syringe visually for particulate matter and discoloration. Note that the syringe is amber colored glass. SUSTOL should not be administered if particulate matter or discoloration is observed, the tip cap is missing or has been tampered with, or if the Luer fitting is missing or dislodged.

Administration Use standard aseptic technique when performing the injection. Administer SUSTOL as a single subcutaneous injection in the skin of the back of the upper arm or in the skin of the abdomen at least one inch away from the umbilicus. Avoid injecting SUSTOL anywhere the skin is burned, hardened, inflamed, swollen, or otherwise compromised [see Warnings and Precautions (5.1)].

Topical anesthetic may be used at the injection site prior to administration of SUSTOL. Due to the viscosity of SUSTOL, the time required for injection is greater than most medications administered subcutaneously. SUSTOL requires a slow, sustained injection which may take up to 20 to 30 seconds. Pressing the plunger harder will NOT expel SUSTOL faster.

2.2 Recommended Dosage

2.2 Recommended Dosage The recommended dosage of SUSTOL is 10 mg administered subcutaneously. Administer SUSTOL in combination with dexamethasone at least 30 minutes before the initiation of MEC or AC combination chemotherapy. Administer SUSTOL on Day 1 of chemotherapy and not more frequently than once every 7 days because of the extended-release properties of the formulation.

For patients receiving MEC, the recommended dexamethasone dosage is 8 mg intravenously on Day 1. For patients receiving AC combination chemotherapy regimens, the recommended dexamethasone dosage is 20 mg intravenously on Day 1, followed by 8 mg orally, twice a day, on Days 2, 3 and 4. If SUSTOL is administered with an NK 1 receptor antagonist, see the prescribing information of the NK 1 receptor antagonist for the recommended dexamethasone dosage.

2.3 Dosage Adjustment in Renal Impairment

2.3 Dosage Adjustment in Renal Impairment In patients with moderate renal impairment (creatinine clearance of 30 to 59 mL/min), administer SUSTOL on Day 1 of chemotherapy and not more frequently than once every 14 days. Avoid SUSTOL in patients with severe renal impairment (creatinine clearance of less than 30 mL/min) [see Use in Specific Populations (8.6)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations, pharmacokinetics)

2.3 Dosage Adjustment in Renal Impairment In patients with moderate renal impairment (creatinine clearance of 30 to 59 mL/min), administer SUSTOL on Day 1 of chemotherapy and not more frequently than once every 14 days. Avoid SUSTOL in patients with severe renal impairment (creatinine clearance of less than 30 mL/min) [see Use in Specific Populations (8.6)].

8.6 Renal Impairment Breakdown products of the polymer vehicle in SUSTOL can be detected in urine of healthy subjects [see Clinical Pharmacology (12.3)]. There are no pharmacokinetic data regarding elimination of the polymer vehicle of SUSTOL in patients with renal impairment and the clinical significance of potential prolonged elimination is not known. Avoid SUSTOL in patients with severe renal impairment. In patients with moderate renal impairment, administer SUSTOL not more frequently than once every 14 days [see Dosage and Administration (2.3)].

Renal Impairment: The total clearance of granisetron was similar in patients with severe renal failure compared to patients with normal renal function following a single 40 mcg/kg intravenous dose of granisetron hydrochloride. Breakdown products of the polymer vehicle in SUSTOL can be detected in urine of healthy subjects [see Clinical Pharmacology (12.3)]. There are no pharmacokinetic data regarding elimination of the polymer vehicle of SUSTOL in patients with renal impairment [see Dosage and Administration (2.3), Use in Specific Populations (8.6)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of SUSTOL in pediatric patients under 18 years of age have not been established. SUSTOL is not recommended for use in pediatric patients less than 12 years of age because the product administration requires a large gauge needle and an extended administration time.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 738 patients administered 10 mg of SUSTOL in the comparator controlled studies, 177 (24%) were 65 and over while 39 (5%) were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients; and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Administration

2.1 Important Administration Instructions For subcutaneous injection only. SUSTOL is intended for administration by a health care provider. SUSTOL is supplied as a refrigerated kit consisting of a single-dose, pre-filled, sterile syringe, a special thin walled 18 Ga 5/8" administration needle, two syringe warming pouches, and a Point Lok ® needle protection device. See the SUSTOL Instructions for Use included in the kit for complete administration instructions with illustrations. Do not substitute non-kit components for any of the components from the kit for administration. Preparation At least 60 minutes prior to administration, remove the SUSTOL kit from refrigeration. Unpack the kit to allow the SUSTOL syringe and all other contents to warm to room temperature. Activate one of the syringe warming pouches, and wrap the SUSTOL syringe in the warming pouch for 5 to 6 minutes to warm SUSTOL to body temperature. Prior to administration, inspect the SUSTOL syringe visually for particulate matter and discoloration. Note that the syringe is amber colored glass. SUSTOL should not be administered if particulate matter or discoloration is observed, the tip cap is missing or has been tampered with, or if the Luer fitting is missing or dislodged. Administration Use standard aseptic technique when performing the injection. Administer SUSTOL as a single subcutaneous injection in the skin of the back of the upper arm or in the skin of the abdomen at least one inch away from the umbilicus. Avoid injecting SUSTOL anywhere the skin is burned, hardened, inflamed, swollen, or otherwise compromised [see Warnings and Precautions ( 5.1 )] . Topical anesthetic may be used at the injection site prior to administration of SUSTOL. Due to the viscosity of SUSTOL, the time required for injection is greater than most medications administered subcutaneously. SUSTOL requires a slow, sustained injection which may take up to 20 to 30 seconds . Pressing the plunger harder will NOT expel SUSTOL faster.

US FDA label

Dosage forms

Philippines

  • Solution for injection: 1 mg/mL
  • ) solution for i.v. injection or infusion: 1 mg/mL (3 mg/mL
  • ) solution for injection: 1 mg/mL (3 mg/3 mL
  • ) solution for injection/infusion: 1 mg/mL (3 mg/3 mL
  • Concentrate for solution for iv infusion: 1 mg/mL
  • Solution for i.v. infusion: 1 mg/mL

Registered products in the Philippines

9 products registered with the Food and Drug Administration (FDA) Philippines list Granisetron as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products9
Philippine FDA-registered products for Granisetron
Package insert
FrezitronGranisetron
1 mg/mL Concentrate for Solution for IV InfusionType I clear and colorless glass ampoule x 1 mL and 3 mL (Box of 5's)
RxVAT-exempt
Labesfal - Laboratorios Almiro, S.A.Portugal
Fresenius Kabi Philippines, Inc.
DR-XY40877
May 15, 2027
GrakytilGranisetron (hydrochloride)
1 mg/mL (3 mg/mL) Solution for I.V. Injection or InfusionType I clear and colorless glass ampoule with red-yellow ring x 3 mL (Box of 5's)
RxVAT-exempt
Mefar Ilac Sanayii A.S.Turkey
Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic, A.S.
DRP-9351
Dec 4, 2030
Grani-AceGranisetron (hydrochloride)
1 mg/mL (3 mg/mL) Solution for I.V. Injection or InfusionType I clear and colorless glass ampoule with red-yellow ring x 3 mL (Box of 5's)
RxVAT-exempt
Mefar Ilac Sanayii A.S.Turkey
Genace Pharma DistributorImporter: Ambica International CorporationTrader: Pharmada Ilac San. Ve Tic, A.S.
DRP-9351-01
Mar 2, 2031
GranimedGranisetron (as hydrochloride)
1 mg/mL (3 mg/3mL) Solution for Injection (IV)Type I Clear and Colorless Glass Ampoule with Red- Yellow ring x 3 mL (Box of 5's) x 3 mL (Box of 10's)
RxVAT-exempt
Akums Drugs & Pharmaceuticals Ltd. (Plant III Injectables)India
Medinova Pharmaceutical Inc.Trader: Unosource Pharma Limited
DRP-17125
Oct 1, 2030
GranonGranisetron (as hydrochloride)
1 mg/mL Solution For Injection (Iv)USP Type I Clear glass ampoule x 1 mL (Box of 5 ampoules in PVC tray)
RxVAT-exempt
PT. Ferron Par PharmaceuticalsIndonesia
PT Dexa Medica
DRP-10621
Nov 19, 2026
GranonGranisetron (as hydrochloride)
1mg/mL Solution for Injection (IV)3 mL in 5 mL-capacity USP Type I Clear glass ampoule (Box of 5 ampoules in PVC tray)
RxVAT-exempt
PT. Ferron Par PharmaceuticalsIndonesia.
Glorious Dexa Mandaya, Inc.Trader: PT Dexa Medica
DRP-10622
Oct 28, 2031
GranzitronGranisetron Hydrochloride
1 mg/mL Solution for Injection (IV)5 mL USP Type I Neutral Borosilicate Glass Ampoule x 3 mL Box of 5’s
RxVAT-exempt
Beijing SL Pharmaceutical Co. Ltd.China
Qualimed Pharma Inc.Importer: Ambica International Corporation
DRP-6960
Dec 16, 2031
KytrilGranisetron
1 mg/mL Solution for I.V. Infusion1 mL Type I Glass Ampule (Box of 5's)
RxVAT-exempt
Cenexi SASFrance
Zuellig Pharma CorporationTrader: Atnahs Pharma UK Limited
DR-XY25012
May 23, 2028
KytronGranisetron (as hydrochloride)
1mg/mL (3 mg/3mL) Solution for Injection/Infusion (I.M./I.V.)Amber Type I Glass Ampoule x 3 mL (Box of 10's)
RxVAT-exempt
Duopharma (M) Sdn. Bhd.Malaysia
DB (Philippines), Inc.
DR-XY48112
Jun 30, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS SUSTOL is supplied as a clear, colorless to slightly yellow, viscous liquid and is available as an: Extended-Release Injection: 10 mg/0.4 mL in a single-dose pre-filled syringe. Extended-Release Injection: 10 mg/0.4 mL in a single-dose, pre-filled syringe. (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Serious or severe injection site reactions (ISRs): Infection, prolonged bleeding, bruising, hematomas, nodules, pain, and tenderness have been reported. Patients who are neutropenic or receiving antiplatelet agents or anticoagulants may be at greater risk. Monitor for ISRs during treatment with SUSTOL. Inform patients that some ISRs may occur 2 weeks or more after SUSTOL administration. For ongoing ISRs, administer SUSTOL at a site away from the affected area and consider discontinuing SUSTOL for severe or persistent ISRs. (5.1)
  • Gastrointestinal disorders: Monitor for constipation and consider optimizing patients' current bowel regimens used for managing preexisting constipation. Also monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. Instruct patients to seek immediate medical care if signs and symptoms of ileus occur. (5.2)
  • Hypersensitivity reactions: Serious reactions have been reported and may occur up to 7 days or longer following SUSTOL administration and may have an extended course. If a reaction occurs, administer appropriate treatment and monitor until signs and symptoms resolve. (5.3)
  • Serotonin syndrome: Reported with 5-HT receptor antagonists alone but particularly with concomitant use of serotonergic drugs. If such symptoms occur, discontinue SUSTOL and initiate supportive treatment. If …
5.1 Serious Injection Site Reactions

5.1 Serious Injection Site Reactions Serious or severe injection site reactions (ISRs), including infections (e.g., abscess, cellulitis with gangrene), prolonged bleeding, bruising, hematomas, nodules, pain, and tenderness have been reported in clinical trials [see Adverse Reactions (6.1)] and/or postmarketing. Some postmarketing cases required emergent medical attention, hospitalization, surgical debridement, intravenous antibiotics, and/or incision and drainage.

Patients who are neutropenic or receiving concomitant anticoagulant and antiplatelet medications may be at greater risk. Monitor patients for development of ISRs during treatment with SUSTOL. Inform patients that some ISRs may occur up to 2 weeks or more after SUSTOL administration. For ongoing ISRs, administer SUSTOL at a site away from the affected area [see Dosage and Administration (2.1)].

Consider discontinuing SUSTOL for severe or persistent ISRs.

5.2 Gastrointestinal Disorders Constipation

5.2 Gastrointestinal Disorders Constipation In clinical trials, 224 of 1131 (20%) of patients treated with SUSTOL 10 mg reported constipation compared to 13% to 15% in the 5-HT 3 receptor antagonist control arms. Hospitalization due to constipation or fecal impaction was reported in 5 SUSTOL-treated patients (0.3%). Monitor patients for the development of constipation while receiving treatment with SUSTOL taking into consideration the extended-release properties of the SUSTOL polymer formulation over at least 5 to 7 days, particularly in patients receiving opioid medications.

Consider optimizing bowel regimens in patients using SUSTOL. Progressive Ileus and Gastric Distention SUSTOL may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of SUSTOL in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.

5.3 Hypersensitivity Reactions

5.3 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported in granisetron-treated patients who have exhibited hypersensitivity to other 5-HT 3 receptor antagonists [see Contraindications (4)]. Avoid SUSTOL in patients who have had hypersensitivity reactions to other 5-HT 3 receptor antagonists [see Contraindications (4)].

Due to the extended-release properties of the SUSTOL polymer formulation, exposure to granisetron may continue for 5 to 7 days following administration. Hypersensitivity reactions may occur up to 7 days or longer following SUSTOL administration and may have an extended course. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur.

If hypersensitivity reactions occur, administer appropriate treatment and monitor patients until signs and symptoms resolve.

5.4 Serotonin Syndrome

5.4 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).

Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT 3 receptor antagonist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT 3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of SUSTOL and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue SUSTOL and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if SUSTOL is used concomitantly with other serotonergic drugs [see Drug Interactions (7.1)].

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS 7.1 Serotonergic Drugs Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue SUSTOL and initiate supportive treatment [see Warnings and Precautions (5.4)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Metabolism Published data suggests that granisetron is metabolized by CYP1A1 and CYP3A4.

Drug Interaction Studies Effect of Other Drugs on Granisetron Granisetron is metabolized by the hepatic cytochrome P-450 drug-metabolizing enzymes CYP1A1 and CYP3A4.

Inducers or inhibitors of CYP1A1 and CYP3A4 enzymes may affect the clearance and half-life of granisetron.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Injection Site Reactions [see Warnings and Precautions (5.1)] Gastrointestinal Disorders [see Warnings and Precautions (5.2)] Hypersensitivity Reactions [see Warnings and Precautions (5.3)] Serotonin Syndrome [see Warnings and Precautions (5.4)] Most common adverse reactions (≥ 3%) are injection site reactions, constipation, fatigue, headache, diarrhea, abdominal pain, insomnia, dyspepsia, dizziness, asthenia, and gastroesophageal reflux. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Heron Therapeutics, Inc. at 844-HERON11 (1-844-437-6611) and www.SUSTOL.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Studies 1 and 2 The safety of a 10 mg subcutaneous dose of SUSTOL was evaluated in two double-blind, randomized, active-controlled studies, in which 210 patients (23%) received MEC and 467 patients (51%) received AC combination chemotherapy (Studies 1 and 2) [see Clinical Studies (14)].

The data described below reflect exposure to a single 10 mg dose of SUSTOL in 924 patients whose mean age was 56 years (range 19 to 91 years); 76% of patients were female; 70% of patients were Caucasian, 16% Asian, 10% Black, and 4% other races. Dexamethasone was co-administered with SUSTOL in Study 1 and Study 2 and an NK 1 receptor antagonist was co-administered with SUSTOL in Study 2.

Table 1 lists the most common adverse reactions reported in at least 3% of patients following a single dose of SUSTOL 10 mg in Study 1 and/or Study 2. Overall, injection site reactions (ISRs) were the most common group of adverse reactions in SUSTOL-treated patients. Specific types of ISRs reported by SUSTOL-treated patients are shown in Table 2.

Table 1. Adverse Reactions Occurring in at Least 3% of Patients Treated with SUSTOL 10 mg in Study 1 and/or Study 2 Study 1 Study 2 Adverse Reaction SUSTOL 10 mg subcutaneous (N=468) % Palonosetron hydrochloride 0.25 mg intravenous (N=463) % SUSTOL 10 mg subcutaneous (N=456) % Ondansetron 0.15 mg/kg intravenous (N=459) % Injection Site Reactions, any Rates of individual injection site reactions (ISRs) are shown in Table 2 37 15 The placebo subcutaneous injection for Study 1 was normal saline and for Study 2 was a SUSTOL-matched control consisting of the SUSTOL polymer vehicle without active drug. 62 See footnote Constipation 14 11 22 15 Fatigue 11 10 21 24 Headache 9 9 13 19 Diarrhea 8 7 9 8 Abdominal Pain 7 7 7 4 Insomnia 4 2 5 6 Dyspepsia 3 3 6 7 Dizziness 3 2 5 5 Asthenia 4 6 2 2 Gastroesophageal Reflux 1 1 5 4 Injection Site Reactions (ISRs) in Studies 1 and 2 Injection site reactions occurred in 37% (175/468) in Study 1, Cycle 1 only, and 62% (281/456) in Study 2 of SUSTOL-treated patients.

The ISR manifestations included pain, erythema, mass/nodule, swelling/induration, and bleeding. The incidence of individual ISRs is shown in Table 2. Patients may have experienced one or more types of injection site reactions; a total of 213 of 924 patients had three or more. ISR reporting procedures included both investigator- and patient-reported outcomes in Study 2, while Study 1 used only investigator reporting.

Table 2. Injection Site Adverse Reactions Following a Single 10 mg SUSTOL Dose Injection Site Reaction Study 1 Treatment Arm (Subcutaneous Injection) Study 2 Patient diary was used in Study 2 to collect ISR information daily., The placebo subcutaneous injection for Study 2 was a SUSTOL-matched control consisting of the SUSTOL polymer vehicle without active drug.

ISR data for this group are not shown. SUSTOL (N=456) % SUSTOL (N=468) % Saline Control (N=463) % Total Subjects with at least 1 ISR 37 15 62 Pain 3 1 20 Tenderness 4 1 27 Bruising/Hematoma 22 10 45 Bleeding 2 1 4 Erythema/Redness 11 3 17 Swelling/Induration 1 0 10 Mass/Nodule 11 1 18 Infection at injection site <1 0 1 Other Other includes injection site discoloration, vesicles, irritation, lipoma, paresthesia, pruritus, rash, reaction, scab, scar, and warmth. 2 1 1 Less common adverse reactions reported in less than 3% of SUSTOL-treated patients in clinical trials are syncope, elevation of serum transaminase levels, pancreatitis, atrial fibrillation, somnolence, flushing, and hypersensitivity reactions (e.g., anaphylaxis, urticaria).

Injection Site Reactions in the Safety Database Reactions at the injection site were assessed in 1814 patients with cancer treated with SUSTOL for one or multiple cycles across four studies (dosing-ranging, open-label, and/or active-controlled), including Study 1 and Study 2. Of the 1814 patients with cancer, 1131 patients were treated with the SUSTOL 10 mg dose.

Additionally, infections at the injection site were assessed in 412 healthy subjects treated with any dose of SUSTOL across single- or multiple-dose studies. Infections: occurred in 7 of 1814 (0.4%) patients with cancer and 1 of 412 (0.2%) healthy subjects in clinical trials. Injection site infections had a median onset of 9 days (range 7 to 16 days) following SUSTOL administration.

One patient who was neutropenic at the time of the infection was hospitalized. All patients with infection were treated with antibiotics and had complete resolution. Bruising and/or hematomas: occurred in 426 of 1131 (38%) patients treated with SUSTOL 10 mg with a median time to onset of 2 days. Injection site bruising and/or hematomas with a delayed onset (onset 5 or more days following SUSTOL administration) were reported in 175 (15%) patients.

Severe bruising or hematoma (e.g., greater than 4 cm bruise or hematoma) occurred in 3% of patients. Patients receiving concomitant anticoagulant and antiplatelet medications were at greater risk for severe injection site bruising and hematomas. Bleeding: occurred in 70 of 1814 (4%) patients treated with SUSTOL. One patient required emergency management.

Injection site bleeding for longer than 5 days was reported in 23 (1%) patients. Pain and tenderness: In a clinical trial that collected information about injection site pain and tenderness from patient diaries, pain with or without tenderness at the injection site was reported by 91 of 456 (20%) patients treated with SUSTOL 10 mg, and an additional 50 of 456 (11%) patients reported tenderness without pain.

Pain and/or tenderness severe enough to require taking pain medication, interfere with patient activity level, or cause significant discomfort at rest was reported in 2% of patients. Among all patients who reported pain and/or tenderness with SUSTOL 10 mg, the median duration was 5 days, and pain lasting longer than 7 days occurred in 6% of patients.

Nodules: occurred in 203 of 1131 (18%) patients treated with SUSTOL 10 mg and persisted for a median of 15 days; 73 patients (6%) had nodules with durations longer than 21 days.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of other formulations of granisetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

System Organ Class Adverse Reactions Cardiovascular bradycardia, chest pain, palpitations, sick sinus syndrome

Adverse reaction frequency tables (US label) US FDA label
Table 1. Adverse Reactions Occurring in at Least 3% of Patients Treated with SUSTOL 10 mg in Study 1 and/or Study 2
Study 1Study 2
Adverse ReactionSUSTOL 10 mg subcutaneous (N=468) %Palonosetron hydrochloride 0.25 mg intravenous (N=463) %SUSTOL 10 mg subcutaneous (N=456) %Ondansetron 0.15 mg/kg intravenous (N=459) %
Injection Site Reactions, anyRates of individual injection site reactions (ISRs) are shown in Table 23715The placebo subcutaneous injection for Study 1 was normal saline and for Study 2 was a SUSTOL-matched control consisting of the SUSTOL polymer vehicle without active drug.62See footnote
Constipation14112215
Fatigue11102124
Headache991319
Diarrhea8798
Abdominal Pain7774
Insomnia4256
Dyspepsia3367
Dizziness3255
Asthenia4622
Gastroesophageal Reflux1154
Table 2. Injection Site Adverse Reactions Following a Single 10 mg SUSTOL Dose
Injection Site ReactionStudy 1 Treatment Arm (Subcutaneous Injection)Study 2Patient diary was used in Study 2 to collect ISR information daily.,The placebo subcutaneous injection for Study 2 was a SUSTOL-matched control consisting of the SUSTOL polymer vehicle without active drug. ISR data for this group are not shown. SUSTOL (N=456) %
SUSTOL (N=468) %Saline Control (N=463) %
Total Subjects with at least 1 ISR371562
Pain3120
Tenderness4127
Bruising/Hematoma221045
Bleeding214
Erythema/Redness11317
Swelling/Induration1010
Mass/Nodule11118
Infection at injection site<101
OtherOther includes injection site discoloration, vesicles, irritation, lipoma, paresthesia, pruritus, rash, reaction, scab, scar, and warmth.211
System Organ Class Adverse Reactions
Cardiovascular bradycardia, chest pain, palpitations, sick sinus syndrome

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no available data on the use of SUSTOL in pregnant women. Limited published data on granisetron use during pregnancy are not sufficient to inform a drug-associated risk. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits administered granisetron hydrochloride during organogenesis at intravenous doses up to 61 times and 41 times respectively the maximum recommended human dose (MRHD) of SUSTOL 10 mg/week [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data Animal Data Reproduction studies with granisetron hydrochloride have been performed in pregnant rats following administration during the period of organogenesis at intravenous doses up to 9 mg/kg/day (approximately 61 times the maximum recommended human dose (MRHD) of SUSTOL 10 mg/week, based on body surface area) and oral doses up to 125 mg/kg/day (approximately 851 times the MRHD of SUSTOL 10 mg/week, based on body surface area). Reproduction studies have been performed in pregnant rabbits in which granisetron hydrochloride was administered during the period of organogenesis at intravenous doses up to 3 mg/kg/day (approximately 41 times the MRHD of SUSTOL 10 mg/week, based on body surface area) and at oral doses up to 32 mg/kg/day (approximately 436 times the MRHD of SUSTOL 10 mg/week, based on body surface area).

These studies did not reveal any evidence of impaired fertility or harm to the fetus due to granisetron hydrochloride. Reproduction studies with the polymer vehicle for SUSTOL have been performed in pregnant rats and rabbits following administration of the polymer vehicle during the period of organogenesis at subcutaneous doses up to 0.295 and 1.18 g per day, respectively, (approximately 45 and 36 times, respectively the amount of polymer vehicle present in the maximum recommended /weekly single human dose of SUSTOL, based on body surface area).

These studies did not reveal any evidence of impaired fertility or harm to the fetus due to the polymer vehicle. A pre and postnatal development study with the polymer vehicle for SUSTOL in rats showed no evidence of any adverse effects on pre and postnatal development at subcutaneous doses (administered on gestation days 7 through lactation day 20) up to 0.295 g per day (approximately 45 times the amount of polymer vehicle present in the maximum recommended /weekly single human dose of SUSTOL, based on body surface area).

Mechanism of action

12.1 Mechanism of Action Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1, 5-HT 1A, 5-HT 1B/C, 5-HT 2; for alpha 1-, alpha 2-, or beta-adrenoreceptors; for dopamine-D 2; or for histamine-H 1; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema.

During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT 3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT 3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin.

In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Cardiac Electrophysiology The effect of SUSTOL on QTc prolongation was evaluated in a double-blind randomized, four-way crossover, placebo and positive (moxifloxacin) controlled study in 51 adult male and female healthy subjects. At 2-fold the recommended dosage of SUSTOL, there was no significant effect on the QTcF interval.

In 142 cancer patients, 24-hour Holter monitoring and 12-lead ECGs were evaluated. QTcF greater than 450 msec were seen in a total of 20 (19%) patients administered SUSTOL and 9 (31%) patients administered intravenous palonosetron hydrochloride. In the SUSTOL group, one patient had a QTcF interval greater than 500 msec and 4 patients had a change from baseline QTcF greater than 60 msec.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination Metabolism: Following a single 10 mg subcutaneous injection of SUSTOL, the terminal elimination half-life of granisetron was approximately 24 hours and was comparable between healthy subjects and patients.

Excretion: Approximately 12% of a granisetron dose, following intravenous administration of granisetron hydrochloride, is eliminated unchanged in the urine in 48 hours.

The remainder of the dose is excreted as metabolites, 49% in the urine and 34% in the feces.

Inducers or inhibitors of CYP1A1 and CYP3A4 enzymes may affect the clearance and half-life of granisetron.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption SUSTOL is an extended-release injection formulation of granisetron using a polymer-based drug delivery system. Following a single-dose administration in healthy subjects, granisetron is released from the polymer over an extended period of time and remains detectable in plasma for 7 days post-dose (Figure 1).

A mean concentration of 3.5 ng/mL (range 0 to 14 ng/mL) was observed at 5 days post-dose [see Warnings and Precautions (5.3)]. Figure 1. Plasma Concentrations of Granisetron Over 7 Days after a Single Subcutaneous Injection of SUSTOL in Healthy Subjects The granisetron pharmacokinetic parameters following injection of SUSTOL were similar between the abdomen and upper arm injection sites as shown in Table 3.

Table 3. Granisetron Pharmacokinetic Parameters Following a Single 10 mg Subcutaneous Injection of SUSTOL in Healthy Subjects by Injection Site Location Parameter Values shown are mean ± SD, except for T max where median [range] are shown. Injection Site Location Abdomen N=113 Upper Arm N=113 C max (ng/mL) 9.8 ± 4.8 10.8 ± 4.6 T max (hours) [range] 12 [1 to 144] 11 [1 to 120] AUC inf, ng.h/mL 680 ± 362 720 ± 366 In patients, peak plasma granisetron concentrations were delayed compared to healthy subjects with a median T max of approximately 24 hours.

Distribution Plasma protein binding of granisetron is approximately 65% and granisetron distributes freely between plasma and red blood cells. Metabolism Published data suggests that granisetron is metabolized by CYP1A1 and CYP3A4. Granisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation.

Elimination Metabolism: Following a single 10 mg subcutaneous injection of SUSTOL, the terminal elimination half-life of granisetron was approximately 24 hours and was comparable between healthy subjects and patients. Granisetron clearance is predominantly by hepatic metabolism. Excretion: Approximately 12% of a granisetron dose, following intravenous administration of granisetron hydrochloride, is eliminated unchanged in the urine in 48 hours.

The remainder of the dose is excreted as metabolites, 49% in the urine and 34% in the feces. Specific Populations Age: Geriatric Population: In a pooled analysis of samples collected from 56 cancer patients in 3 clinical studies, the mean C max and mean AUC 0-inf for granisetron following subcutaneous administration of a 10 mg dose of SUSTOL was 39% and 76% higher in patients 65 years of age and older than in patients less than 65 years of age.

These pharmacokinetic differences are not considered clinically meaningful taking into consideration the small number of patients 65 years of age and older in the analysis (n = 16) and the high inter-patient variability. Sex: In a pooled analysis of samples collected from 56 cancer patients in 3 clinical studies, the mean C max and mean AUC 0-inf for granisetron following subcutaneous administration of a 10 mg dose of SUSTOL was 34% and 132% higher in males than in females.

These pharmacokinetic differences are not considered meaningful taking into consideration the small number of males in the analysis (n = 13) and the high inter-patient variability. Renal Impairment: The total clearance of granisetron was similar in patients with severe renal failure compared to patients with normal renal function following a single 40 mcg/kg intravenous dose of granisetron hydrochloride.

Breakdown products of the polymer vehicle in SUSTOL can be detected in urine of healthy subjects [see Clinical Pharmacology (12.3)]. There are no pharmacokinetic data regarding elimination of the polymer vehicle of SUSTOL in patients with renal impairment [see Dosage and Administration (2.3), Use in Specific Populations (8.6)].

Hepatic Impairment: The total clearance of granisetron was approximately 50% lower in patients with hepatic impairment (neoplastic liver disease) compared to patients with normal hepatic function following a single 40 mcg/kg intravenous dose of granisetron hydrochloride. The high inter-subject variability in the pharmacokinetic parameters of granisetron in patients with hepatic impairment limits the interpretation of these findings.

Drug Interaction Studies Effect of Other Drugs on Granisetron Granisetron is metabolized by the hepatic cytochrome P-450 drug-metabolizing enzymes CYP1A1 and CYP3A4. Inducers or inhibitors of CYP1A1 and CYP3A4 enzymes may affect the clearance and half-life of granisetron. In in vitro human microsomal studies, ketoconazole inhibited ring oxidation of granisetron.

However, the potential for an in vivo pharmacokinetic interaction with ketoconazole is not known. Phenobarbital: Administration of intravenous granisetron hydrochloride with phenobarbital, an enzyme inducer, resulted in a 25% increase in total plasma clearance of granisetron. The clinical significance of this interaction is not known.

Effect of Granisetron on Other Drugs Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro. In addition, the in vitro activity of the cytochrome P-450 subfamily 3A4, which is involved in the metabolism of some narcotic analgesics, is not modified by granisetron. Polymer Breakdown Products In a metabolic fate study conducted in healthy subjects, breakdown products of the triethylene glycol poly(orthoester) polymer vehicle of the SUSTOL formulation including triethylene glycol (TEG), pentaerythritol (PE), and the oxidative metabolite of TEG, triethylene glycol monocarboxylic acid (TEG acid) were detected in urine with incomplete recovery by the end of study period (10 days).

Accumulation of these metabolites in plasma was not noted. The recovery of the polymer load was incomplete in this study and could be due to insufficient sampling and assay sensitivity issues preventing detection of additional metabolites [see Dosage and Administration (2.3), Use in Specific Populations (8.6)]. image of figure 1

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. SUSTOL · Heron Therapeutics, Inc. [US FDA-approved label, version 11, April 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7c7ffdd-8270-4030-bc1e-a1cb28a6de56
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .